Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or IdelalisibJeffrey A. Jones, Steven Coutré, Matthew S. Davids et al.|Blood|2016Cited by 58
Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.Jeffrey A. Jones, Steven Coutré, William G. Wierda et al.|Journal of Clinical Oncology|2016Cited by 22